This report describes the use of medications as a proxy when medical record reviews are unavailable, to study the health effects of residents environmentally exposed to air-manganese (n = 185) compared to unexposed residents (n = 90). Participants' current medication lists and medication questionnaire responses were collected in clinical interviews and categorized into 13 domains. Exposed participants reported fewer hours of sleep than controls (6.6 vs. 7.0). The exposed used significantly more medications than unexposed participants (82.2 % vs. 67.8 %) and, when adjusting for age, education, and personal income, also for pain (aOR = 2.40) and hypothyroidism (aOR = 7.03). Exposed participants with higher airMn concentrations, monitored for 10 years by the U.S. Environmental Protection Agency, were 1.5 times more likely to take pain medications. The exposed participants take significantly more medications than unexposed participants in the categories of hypothyroidism, pain, supplements, and total medications.
Introduction
Manganese (Mn) is an essential element with natural low levels ubiquitously found in water, food, and air. However, due to industrialized processes, both workplace and environmental exposures to Mn have increased (Mergler et al. 1999; Santos-Burgoa et al. 2001; Solís-Vivanco et al. 2009 ). In 2009, an estimated 928,727 pounds of Mn from over 1,900 different facilities were released into the air in the US, accounting for roughly 7 % of all facility released pollutants (Agency for Toxic Substances and Disease Registry [ATSDR] 2012). Occupational studies have reported health problems among workers, especially those working without adequate protection and ventilation, who manufacture steel, add Mn to paints and glazes, and weld (Roels et al. 1987) . Additionally, residents who have been exposed to environmental Mn near industrial sources, such as smelters, have developed health consequences similar to those described in occupational settings (Feldman 1999) . Residential and occupational studies have identified deficits in motor, tremor, and cognitive functions with inhalation exposure to Mn in the air (Mergler et al. 1999; Rodríguez-Agudelo et al. 2006; Solís-Vivanco et al. 2009; Kim et al. 2011; . General environmental ambient air-Mn (Mn/A) exposures are typically significantly lower than in occupational study settings .
The mood, cognitive, motor, and neurological impairments associated with elevated Mn exposure, described as Mn-induced parkinsonism, (Feldman 1999; Cersosimo & Koller 2006) differ slightly from Parkinson's disease but share similarities of psychomotor abnormalities, tremor, bradykinesia, and postural sway. This indicates that Mn-induced parkinsonism is not easily separable from idiopathic Parkinson's disease (Rutchik et al. 2012; Andruska & Racette 2015) . Other medical conditions currently associated with Mn exposure include hypertension (Lee & Kim 2011) , hypotension (Šarić & Hrustić 1975; Jiang & Zheng 2005) , hypothyroidism (Soldin & Aschner 2008) , and diabetes (Forte et al. 2013) .
The association between blood pressure and Mn is controversial. Former studies (Šarić & Hrustić 1975; Jiang & Zheng 2005 ) of workers exposed to Mn/A found participants were more likely to have hypotension, however, most recently Lee and Kim (2011) found increased blood pressure was associated with increased blood Mn levels in a sample of adult men and women, even after controlling for other heavy metals (blood lead, mercury, and cadmium).
Very little is known about the effects of overexposure to Mn on thyroid homeostasis. In a review of the current literature, Soldin and Aschner (2008) reported that overexposure to Mn may directly or indirectly cause hypothyroidism through the dopaminergic dysregulation of the thyroid-stimulating hormone (TSH), resulting in decreased thyroid hormone synthesis. In an animal study, rats were given a Mn-rich diet for five weeks, after which decreased serum TSH concentrations were found as a result of Mn accumulation (Buthieau & Autissier 1983) .
In addition to decreased blood pressure and thyroid hormone function, overexposure to Mn has been associated with complications in respiratory and cardiac function, pain with muscle cramps, headaches, and sleep disturbances (Crossgrove & Zheng 2004; Soldin & Aschner 2008) . Contrastingly, previous studies have identified the prevalence of diabetes to be increased in those with low levels of blood Mn (Forte et al. 2013 ).
Self-report of medication use in epidemiologic studies
In recent decades, adult environmental studies of Mn exposure have reported physical (Santos-Burgoa et al. 2001; Haynes et al. 2010; Kim et al. 2015) and mental health problems identified through cognitive , mood (Bowler et al. 2012), motor, and neurological ( Rodríguez-Agudelo et al. 2006; Kim et al. 2011; testing of study subjects, but medical record reviews for exposed residents are rare in the literature. When medical records and clinical testing are unavailable, examination of residents' current prescribed medication use (Dayal et al. 1994; Zmirou et al. 1994; Bowler et al. 2002) has been used as a proxy of health effects associated with Mn or other neurotoxic chemical exposures. Bowler et al. (2002) reported increased medication use in a Northern California community in an accidental Catacarb chemical release from an adjacent oil refinery when residents were compared to a similar control town. Medication use after a spill of hydrofluoric acid in Texas was also described by Dayal et al. (1994) . In a study by Kehoe et al. (1994) , the authors compared 1,380 participants' self-reported medication use with physician-reported use and found very few differences, suggesting accurate recall of medication use, especially when concerning chronic conditions, see also (Harlow & Linet 1989; Kriegsman et al. 1996) . Agreement between self-reported medication recall and pharmaceutical records ranges between 75 and 87 % (West et al. 1995) . Participants were shown to under-report rather than over-report their medication use.
When self-reported questionnaire data on medication use is supplemented with personal interviews, the accuracy of recall is further increased (Bergmann et al. 2004) . This methodology, which is used in the current study, helps to limit any recall biases on self-report questionnaires alone and improves the accuracy of medication history recall.
The objective of this present study was to evaluate currently prescribed medications, over-thecounter medications, and herbal supplements in residents of two towns with elevated Mn/A compared to residents in an unexposed comparison town.
This study is the first report of medication use as a potential indicator of human health effects in adult residents of the United States who have been exposed to elevated modeled Mn/A concentrations in the environment.
Methods

Study design and participant selection
A cross-sectional study design was used in this health study conducted in three Ohio towns , two with reported high levels of Mn/A (Marietta and East Liverpool) and one town which is demographically similar, but unexposed to Mn/A (Mount Vernon). East Liverpool was reported by the U.S. Environmental Protection Agency (EPA) to have the highest measured concentrations of respirable Mn/A in the U.S. (U.S. EPA 2012) . Mn/A emissions in Marietta were also reported to be among the highest in the U.S. (U.S. EPA 2011) .
Residents of Marietta, Ohio reside in close proximity to a ferromanganese smelter, whose operations began in the early 1950s (U.S. EPA 2010). Over 10 years of air-sampling, conducted by the Ohio EPA, found consistently elevated levels of Mn/A (ATSDR 2007 ) as a result of long-term emissions from Eramet Marietta, Inc. Residents from East Liverpool, Ohio were shown to have high Mn/A (ATSDR 2010 ) from an open-air Mn storage and packaging facility, which began operations in the late 1960s.
Mount Vernon, Ohio was chosen as the unexposed comparison town because it is demographically very similar (U.S. Census Bureau 2001a , 2001b to both Marietta and East Liverpool, as well as the state of Ohio. Mount Vernon also has a low number of major industries (U.S. EPA 2011) and consequently, the Ohio EPA (2010) and U.S. EPA (2011) have reported no area air pollution control activities related to toxic metals and particulate emissions. In the Mount Vernon participant recruitment zone, Mn/A emissions were slightly above background levels from long-range transport, natural emissions, and other unknown sources (U.S. EPA 2009 (U.S. EPA , 2011 .
Study participant recruitment
Recruitment of study participants has been described in more detail elsewhere Bowler et al. 2012) . In each of the three towns, recruitment letters were sent to selected residents, inviting them to participate in the study. The goal was to recruit 100 participants per town. Study participants in the exposed and unexposed towns were randomly selected (Marietta and Mt. Vernon only) using county parcel and water records within the local zip codes, purchased mailing lists, and reverse address lists. Residents of Marietta were selected within a 12 air-miles zone from the exposure source, which emitted fine Mn/A particulate during the high temperature industrial processes of a ferromanganese smelter. The particle sizes from the Mn storage and packaging facility in East Liverpool were slightly larger than those from the Marietta smelter. Larger airborne particles travel a shorter distance and, therefore required a smaller study area equal to or less than a 2 air-miles radius from the source (ATSDR 2010) . Because of the small geographic study area for East Liverpool, all residents in the 2 air-miles radius were invited to participate.
In Marietta, 1,732 letters were sent to eligible residents, to which 187 responded with interest, 122 participants were eligible, and 100 were tested. In East Liverpool, 1,309 letters were sent, to which 192 responded with interest, 123 participants were eligible, and 86 were tested (14 residents did not attend their appointment). In Mount Vernon, 2,297 recruitment letters were sent and 245 individuals indicated interest by responding with provided postcards. Of those, 117 were eligible and 100 were recruited, with the remaining 17 being unable to attend due to personal scheduling conflicts.
Ultimately, 90 participants were tested (9 residents did not attend their appointment and 1 participant was excluded post-testing).
Study inclusion and exclusion criteria
In all three towns, a maximum of two residents per household were included in the study, provided they had lived in their respective towns for a minimum of 10 years and were between the ages of 30-75 years. Interested residents were excluded if they did not meet the age and residence criteria or if they had met one of the exclusion criteria, described by Bowler et al. (2012) . These exclusion criteria consisted of having a diagnosed neurodegenerative disease (multiple sclerosis, Alzheimer's dementia, Huntington's chorea, and PD), brain ailments (meningitis, encephalitis, stroke with hospitalization for more than one day, brain surgery, prior head injury, and epilepsy), psychiatric conditions ( schizophrenia, major psychiatric diagnosis, and bipolar disorder), receiving current medical treatment (anticonvulsive, alcohol/drug dependence, and hepatic condition), being pregnant or nursing, medically unable to participate in the study, having exposure to hazardous chemicals other than Mn (pesticides, fungicides, herbicides, carbon monoxide, and neurotoxic metals), including ever working at one of the Mn emission sources or having lived in the other exposed town. An a priori decision was made to recruit and test 100 participants from each town.
At the conclusion of the residents' participation in the health study, participants were each given a $50 gift certificate to a local retail store. The institutional review board of both San Francisco State University (SFSU) and the Ohio Department of Health (ODH) granted research approval. Written informed consent of residents was gathered prior to data collection. The ODH, US EPA, Ohio EPA, and the ATSDR provided technical assistance, study design input, and review of the SFSU protocol.
Data collection
All three towns had the same method of test administration using the same neurological and neuropsychological measures in addition to personal interviews with the clinical neuropsychologist (RB). This methodology is further described in previous manuscripts Kim et al. 2015) .
The neuropsychologist interviewed each participant regarding his or her health concerns and medication use. Prior to the interviews, the participants completed a self-reported health questionnaire, which included demographic information, lifestyle factors, work history data, and medical background information, including symptoms and medication use. The health questionnaire was developed with the input of neurologists, internal medicine specialists, neurotoxicologists, and neuropsychologists.
In addition to the medications reported by each participant in the health questionnaire, participants were asked to bring their prescription medications or a list of the names of their prescribed medications and supplements to their personal interview.
From the health questionnaires and lists of currently prescribed medications and supplements, the medical co-authors and specialists in occupational (YK) and psychiatric medicine (AB), independently derived 12 categories of medications with one additional category for over-the-counter supplements (see Table 1 ). The level of inter-rater agreement for the placement of medications into categories was 100 %.
Mn/A exposure estimates for the two exposed towns
Personal Mn/A exposure for each participating residential address was estimated using the U.S. EPA's AERMOD dispersion model data calibrated with Mn/A measurements of total suspended particulates (TSP), collected over a 10-year period from 2003 to 2013 for the two exposed towns from monitors operated by Ohio EPA. This methodology is discussed in further detail by Colledge et al. (2015) . Briefly, a generic area emissions rate of 1 gram per second was assumed over the entire surface area of the two source facilities, yielding off-site concentrations at all study subject receptor locations and area air monitoring sites. One air monitoring site was selected as the reference monitor in each community, and the concentrations modeled at the receptors were scaled to this reference location as a ratio. The air data collected at the reference monitor were multiplied by the modeled receptor ratio to yield an estimated long-term average exposure for each study subject. The air sampling method and Mn analyses were identical for both exposed towns. The ATSDR minimal risk level is 0.3 μg/m 3 (ATSDR 2012 Those participants who lived further away from the Mn point source had lower modeled mean average Mn/A levels. Participants from the two exposed towns had stable and long residential histories with ongoing exposure to Mn in air. The mean length of residence was 37 years in Marietta and 47 years in East Liverpool. 
Statistical analyses
The participants from the Mn exposed towns of Marietta and East Liverpool were combined into one group for analyses to achieve sufficient power. This was acceptable because we used the same methods to estimate exposure within the two towns. For the purposes of this study, the participants from the two exposed towns will be referred to as the 'exposed group, ' whereas the participants from the unexposed comparison town will be referred to as the 'unexposed group. ' One participant from the exposed group was excluded from these analyses because no information on medication use was provided. Differences in demographic variables between exposed and unexposed groups were evaluated using chi-square tests. Preliminary analysis of data for the number of sick days reported over a two-year period revealed several outliers in the dataset who reported being sick every day. Therefore, all cases with extreme values, defined as a z-score of ±1.96, were excluded. This resulted in the removal of five cases solely for the comparison of reported sick days between the exposed and unexposed group. The combined participants from the exposed group (n = 185) and unexposed (n = 90) group were compared on the established 12 medication and 1 supplement categories using independent samples t-tests and chi-square (χ 2 ) tests, as appropriate. Cramer's V was used to compute effect sizes. In order to control familywise error associated with conducting multiple statistical comparisons, the per-comparison significance level was adjusted using the false discovery rate procedure outlined by Benjamini and Hochberg (1995) . International Classification of Diseases (ICD) codes were assigned by the senior physician co-author (YK) to determine if exposure groups differed regarding illnesses. Chi-square analyses between the exposed and unexposed groups regarding illnesses by ICD code (respiratory, thyroid, cardiac, digestive, arthritis/osteoporosis, diabetes, mental illness, and having had cancer) showed no differences.
The chi-square analyses were also used as preliminary analyses for hierarchical logistic regressions between medication category and exposure group. The significant medication categories from the chisquare analyses were further analyzed using hierarchical binomial logistic regression. Hierarchical binomial logistic regressions were performed to determine whether exposure predicted current medication use by category when controlling for the effects of age, education, and personal income. For the evaluation of hypothyroid medications, sex was added as a covariate to the model to control for hypothesized differences described by Aoki et al. (2007) . Years of residence in the respective town was not included in the regression model because of the significant co-linearity and strong zero-order correlation between years of age and years of residence (r = 0.460, p < 0.001).
To further explore the relationship of medication use in the exposed group, estimated modeled concentrations of Mn (AERMOD) were analyzed with medication category, using binomial logistic regressions. No measurements of Mn/A concentrations for the unexposed group were available.
Results
Demographic, lifestyle factors, and health characteristics for participants from the exposed groups (n = 185) and unexposed group (n = 90) are shown in Table 2 . The exposed group had significantly fewer years of education (13.8 vs. 15.2 years) and significantly more years of residence in their respective town (41.1 vs. 33.6 years). Additionally, the exposed group reported significantly fewer hours of sleep per night (6.6 vs. 7.0 h) than the unexposed group. They also reported significantly (p = 0.007) higher percentage of current medication use than the unexposed group (82.2 % vs. 67.8 %).
When asked about work status, 8.2 % of the exposed (E) group and 3.4 % of the unexposed (U) group reported being disabled. A review of the reasons for being disabled revealed that the disabilities were primarily for orthopedic injuries (E = 3.8 %, U = 3.3 %); and the remainder were from the exposed group within the following categories: cancer (2.2 %), respiratory (1.1 %), and cardiac (0.5 %). Examination of the differences in medication use by category of those disabled compared to the non-disabled indicated that they differed on depression and respiratory medication use, with disabled residents using more medications. Table 3 shows the association between exposure group Table 2 . Demographic, lifestyle factors, and exposure characteristics for unexposed and exposed groups with means, standard deviations, frequencies, and t-test/chi-square results. Table 4 and Figure 1 show the hierarchical binomial logistic regression results and the estimated adjusted odd ratios of taking medication by category for both groups. Exposure group significantly Table 3 . number of participants taking medications by category for all groups combined and unexposed vs. exposed groups. *significant at p ≤ 0.02, corrected Benjamini-Hochberg significance level.
Medication category
All groups (N = 275) Unexposed (n = 90) predicted the use of hypothyroid medication, pain medication, supplements, and total prescribed medications above and beyond the control variables of age, education, and personal income. Exposure did not significantly predict medication use for other medication categories. Using Nagelkerke's R 2 as a description of variance, the model explained 25 % of the variance between groups for hypothyroid medication and 9 % of the variance for pain. Participants from the Mn-exposed towns were 8.07 times more likely to take hypothyroid medication (95 % CI [1.80, 36.16]) and 2.44 times more likely to take pain medication (95 % CI [1.27, 4.69]). Exposed participants were also 2.33 times more likely to take prescription medication in general (95 % CI [1.21, 4.48]) and 3.40 times more likely to take supplements (95 % CI [1.54, 7.49]). Using Nagelkerke's R 2 as a description of variance, the model explained 19 % of the variance between groups for using medications in general and 17 % of the variance between groups for supplement use. As illustrated in Table 4 , increasing age was significantly associated with an increased likelihood of prescribed medication use; however, age was not associated with increased use of medications within specific categories.
Because 10 years of modeled Mn/A concentration data were available for the exposure zones, supplementary analyses were conducted to determine whether the level of exposure predicted medication use for Mn-exposed participants, while controlling for age, education, and personal income. Exposed participants were 1.55 times more likely to take pain medication (95 % CI [1.04, 2.30]) for every one unit increase in Mn/A concentration. Using Nagelkerke's R 2 as a description of variance, increased modeled Mn/A explained 9 % of the variance for the use of pain medications and 6 % for hypothyroid medications. Mn/A did not correlate with the total number of symptoms self-reported by exposed participants in a questionnaire (r s = 0.04, p = 0.645).
Discussion
Medical record reviews of Mn-exposed persons are rare in the neurotoxicologic literature. This study examined Mn health consequences, using current medications as a proxy for medical record review in a Mn-exposed and unexposed group. Dayal et al. (1994) suggested that using prescribed medication data as a measurement of health may be a more reliable procedure than self-report of symptoms or illnesses. This study examined the health effects of Mn exposure by comparing demographically similar residents from two Mn-exposed towns of Marietta and East Liverpool, Ohio, with the unexposed town of Mount Vernon. Examination of medication lists brought by participants and endorsements of medication use in completed health questionnaires indicated that the Mn-exposed group used significantly more medications than the unexposed group.
Studies examining the adverse health effects of environmental Mn exposure have increased in the last decade internationally (Rodríguez-Agudelo et al. 2006; Solís-Vivanco et al. 2009; Haynes et al. 2010) . Parkinsonism, and with extremely high exposures, manganism, is associated with differentiating symptoms, signs, and other adverse health effects, as described by Feldman (1999) , while others (as cited on the first page of our introduction) cite mood, motor, tremor, and cognitive functions. In this study, an increase in medication use was found for the categories of hypothyroidism and pain, as well as total medications, suggesting adverse physical health among participants from the Mn-exposed towns. Exposed participants also reported taking more supplements than the unexposed to prevent or ameliorate illness.
Prevalence rates of hypothyroidism in the United States' general population range from 3.7 to 4.6 % (Aoki et al. 2007; Golden et al. 2009 ). In the current study, 4.4 % of participants from the unexposed town used medication for hypothyroidism. When examining the Mn-exposed group, the use of hypothyroid medication was over three times more prevalent (15.1 %). Taking medication for hypothyroidism was not associated with taking medications from any of the other medication categories. Hypothyroidism, with exposure to Mn/A in residents, has not previously been reported.
Alterations in the levels of Mn in blood can result in metabolic dysfunction and is found in certain diseases. A significant increase in blood Mn has been described in people diagnosed with hypothyroidism (Soldin & Aschner 2008) , which may be the result of an interaction between Mn and thyroid hormone homeostasis. The results of this study may support the Soldin and Aschner (2008) postulation of an interaction between higher concentrations of Mn and dysfunctional thyroid hormone homeostasis. A similar homeostatic relationship was found in persons with diabetes, however previous studies have found blood Mn levels are lower in those with diabetes (Forte et al. 2013) . Lee and Kim (2011) reported log blood Mn relationships for both systolic and diastolic blood pressure when controlling for sex, age, regional area, education, smoking/drinking status, hemoglobin, and serum creatinine, in a representative sample of the Korean National Health and Nutrition Examination Survey 2008 survey. The current study, however, found no association between the Mn/A-exposed participants and the unexposed group for hypotension or hypertension and diabetes.
The prevalence of GI disease in the U.S., particularly gastroesophageal reflux disease, is estimated at 20 % (Dent et al. 2005 ) with 16 % of symptomatic people taking medication (Isolauri & Laippala 1995) . In this study, 22.7 % of Mn-exposed and 10 % of unexposed participants use GI medication. In the exposed group, GI medication use was significantly associated with pain medication use. Provided this relationship, it is likely that the exposed participants' GI medication use was for the purpose of treating the GI side effects, which are frequently associated with chronic pain medication use (Bhatt et al. 2008) .
The prevalence of chronic pain -pain that is recurrent, lasting at least 6 months -in the U.S. is estimated at 30.7 % (95 % CI [29.8, 31 .7]) (Johannes et al. 2010 ). In the current study, 16.6 % of unexposed participants used medication for pain management, while participants from the Mn-exposed towns used pain medications at a higher rate of 37.2 %, making the prevalence of pain in the exposed group higher than that reported in the U.S. general population. As shown in Table 4 , those residents with Mn exposure were more than twice as likely to use medication for pain. When examining Mn/A concentrations across the exposed group only, higher concentrations of Mn/A were also associated with more pain medication use. The majority of pain medications were used to treat headaches or migraines, but non-steroidal anti-inflammatory medicine and muscle relaxants were also used by Mn-exposed participants. Headaches and muscle cramps have been identified as early manifestations of Mn toxicity in humans (Jiang & Zheng 2005; Forte et al. 2013) . It is hypothesized that muscle cramps could be the result of long-term Mn exposure and the development of dystonia, hypokinesia, or muscle rigidity, common in Mn-exposed populations (Pal et al. 1999 ). Further research is needed to develop a causal model between Mn/A and chronic pain. This is the first report of an association between Mn exposure as well as higher concentrations of Mn/A and the prevalence of chronic pain.
The occupational literature describes the onset of Parkinsonism from Mn overexposure as manganism. Symptoms at that point are similar to Parkinson's disease and include dystonia, gait abnormalities, bradykinesia, and rigidity (Guilarte 2010; Guilarte & Gonzales 2015) . However, as the literature indicates, motor disturbances in Mn-exposed persons are resistant to levodopa medication (Guilarte et al. 2006) and Mn-affected persons may use more medications to ameliorate their health problems. Mn exposure and subsequent disturbances may worsen pre-existing medical conditions, resulting in increased medication use.
Limitations of the study
The principal investigator (PI) discussed the medication lists with each participant and verified the medications in the health questionnaire. However, the medication lists were more specific as to the name of each medication and more fully represent the current medication use of the participants. A limitation of the study is the self-reported nature of the medication and subsequent lack of independent validation of the participants' medications with their medical records. According to West et al. 1995 , it is more likely that if inaccuracies exist, they are the result of under-reporting medications. For that reason, health conditions may be slightly under-reported. Although review of medical records is desirable, it may not be practical in large epidemiologic studies.
Although there are refined Mn/A measurements and exposure modeling for both East Liverpool and Marietta, OH, there are no Mn/A exposure data for Mount Vernon, OH. However, no significant industrial sources of manganese were identified in Mount Vernon when an unexposed population was in the process of being selected. Moreover, no personal air sampling was available in Mount Vernon, but the Toxic Release Inventory (TRI) data from 2010 (U.S. EPA 2010) indicated insignificant levels of Mn/A in Mount Vernon, the source of which was largely long-range transportation and other natural emissions.
A follow-up study is desirable to both evaluate more long-term medication use and determine the causal relationship between Mn exposure and adverse health. Not all residents studied may have received regular medical care and their adverse health effects are not known.
Strengths of the study
Although many occupational and some environmental studies of Mn exposure have shown adverse health function, this is the first environmental study of increased medication use in adult-exposed residents in the U.S.. Reported use of a specific medication is likely more objective, avoids recall bias, and is likely less inflated than would be a review of self-reported symptoms alone (Dayal et al. 1994) .
Power analysis confirmed that the number of residents in the combined exposed towns was sufficient to satisfy the study requirements. The methodology used in the three towns was identical. All three towns were similar in size as were most demographic characteristics according to the 2008-2012 U.S. Census Bureau (2014) . A careful cross-sectional study design, recruitment, and final selection of residents using strict inclusion/exclusion criteria assured the elimination of other illnesses similar to those from Mn such as Parkinson's disease. The study also controlled for the potential of confounding illnesses. Interviews with each of the 275 residents, who brought their medication lists to the PI, assured an accurate review of medications as a surrogate of medical health and added strength to the study. Additionally, two co-author physicians, one in occupational medicine (YK) and one in psychiatry (AB) reviewed all of the individual medications and assisted in forming the medication categories.
Moreover, the 10-year monitoring of Mn/A in the exposure zones of East Liverpool and Marietta and air dispersion modeling permitted analyses of Mn concentration associations with medications used.
Use of the local unexposed town's medication data, in addition to prevalence data in the U.S., suggested that the greater use of current medication use for hypothyroidism and pain health problems may be an outcome of environmental Mn exposure. Moreover, in examining modeled concentrations of Mn/A exposure within the exposed towns only revealed higher modeled concentrations of Mn/A were associated with increased use of pain medications. Current medication use can be an informative surrogate for medication record review.
Conclusions
This first environmental study of Mn/A-exposed adults and medication use indicates a higher prevalence of medication use for hypothyroidism and pain health problems among the Mn/A-exposed group. Medication use may be a better method of classifying adverse health outcomes compared to using generalized self-reports of health complaints.
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